Weekly Policy Update: CBSA Submits Comment Letter to Senate Finance Committee’s Health Task Force Urging Repeal of the Medical Device Excise Tax
By: Colorado BioScience Association Date: 06/14/2019
Last month, leaders of the Senate Finance Committee announced the formation of several bipartisan task forces to examine 42 temporary tax provisions that expired or will expire between December 31, 20...
Learn MoreCutisPharma Announces Acquisition of Silvergate Pharmaceuticals, Name Change to Azurity Pharmaceuticals
By: Colorado BioScience Association Date: 06/13/2019
WOBURN, Mass. (Jun. 12, 2019) – CutisPharma, Inc. announced today its acquisition of Silvergate Pharmaceuticals, Inc. and the unveiling of its new corporate brand for the unified company: Azurity Phar...
Learn MoreWeekly Policy Update: CBSA Attends the 2019 BIO International Convention
By: Colorado BioScience Association Date: 06/10/2019
Last week CBSA President and CEO Jennifer Jones Paton and Vice President Emily Roberts attended the 2019 BIO International Convention in Philadelphia. The event brings together over 16,000 attendees f...
Learn MoreColorado BioScience Association Celebrates State’s Collaborative Nature
By: Colorado BioScience Association Date: 06/03/2019
New Magazine Offers In-Depth Financing Data and Insights on Medical Device and Drug Approvals DENVER – Colorado BioScience Association (CBSA) today launched the new issue of its annual magazine, BioSc...
Learn MoreImproving the Reimbursement Landscape for Medical Technology Innovators
By: Colorado BioScience Association Date: 05/24/2019
CBSA continues to work with Congress and federal policymakers to improve the reimbursement landscape for medical technology innovators. Even when groundbreaking and innovative technologies meet FDA’s...
Learn More27 Companies Share 6.1 Million Dollars in 2019 Advanced Industries Accelerator Grants
By: Colorado BioScience Association Date: 05/22/2019
Colorado BioScience Association congratulates the 27 companies recently recognized as valuable investments for the entire state by the Office of Economic Development and International Trade’s (OEDIT)...
Learn MoreCMS Rolls Back Harmful Proposals in Medicare Part D
By: Colorado BioScience Association Date: 05/20/2019
Last Thursday CMS finalized a rule on Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses, which included a number of significant changes to the proposed r...
Learn MoreWeekly Policy Update: CMS Proposed Rule is a Step Forward for the Coverage of Breakthrough Technologies
By: Colorado BioScience Association Date: 05/13/2019
In late April, the Centers for Medicare and Medicaid Services (CMS) publicly released its FY 2020 Inpatient Prospective Payment System (IPPS) Proposed Rule. The rule is a critical step forward for cov...
Learn MoreWeekly Policy Update: The Final Tally - 2019 Legislative Session Comes to a Close
By: Colorado BioScience Association Date: 05/03/2019
CBSA has worked hard this session to advocate on behalf of the industry. We’ve worked with our members and partners to advance proposals that promote patient safety, protect patient access, and enhanc...
Learn MoreWeekly Policy Update: One Week Left - What Will Make It Across the Finish Line
By: Colorado BioScience Association Date: 04/26/2019
With just over a week left in the 2019 legislative session, there are hundreds of bills left to debate and Democrats are scrambling to get their remaining priorities across the finish line. Here are s...
Learn More